CatSci Ltd is incredibly proud to announce the appointment of Dr Gary Parsons as our new Director of Pharmaceutical Development. Gary’s appointment will enable us to continually offer more and better to our customers so that they can deliver much-needed therapeutics into the hands of patients around the globe. His role is a step towards CatSci’s vision of becoming a fully integrated CMC partner that accelerates medicines development.
Gary has worked in the pharmaceutical industry since he completed his PhD at the University of London; he began in formulation development roles, gaining experience across multiple types of medicine and drug substances including small molecules, proteins and RNA-based therapeutics. He has held several senior Director roles, including the global leadership of early-phase developability and product design departments focussing on acceleration to clinical studies. He has notable expertise in inhaled product development, having worked across all phases of development, from lead optimisation to initial commercial supply in support of the creation of GSK’s Ellipta portfolio of inhaled medicines. His experience and expertise make him the perfect fit for our ambitious plans for further growth.
Gary said, “I am thrilled to be joining the CatSci team, especially at such a pivotal point in their evolution. I look forward to applying my breadth of knowledge and experience to help create medicines that are safe, effective, and will make the lives of patients better.
I am particularly excited at the prospect of integrating API material science into dosage form design so that we can help customers can make the right decisions earlier in the development process, whilst providing the flexibility and optionality that they are looking for.”
Our COO, Dr Simon Tyler, said: “It’s a privilege to be able to announce Gary’s appointment. His many years of leadership experience and technical impact, typified by his work in inhalation product R&D, were obvious from the very first meeting with us. His passion for innovative pharmaceutical development makes him ideal to develop and deliver our particle-to-product strategy. He will be working within our growing medicines development capability that seeks to empower scientists across drug substance and drug product development to expedite the launch of best-in-class therapeutics.”
Over the next 12 months, CatSci has ambitious plans to continue to expand our capabilities and offerings; we aim to break down silos between drug substance and drug product development. Gary’s appointment is another step on that journey, he will be influential in building out our integrated capability, enabling us to de-risk the pharmaceutical pipeline of our customers and advance more therapeutics towards launch.
